Darbepoetin Alfa Impact on Health Status in Diabetes Patients with Kidney Disease
- 1 April 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of the American Society of Nephrology
- Vol. 6 (4), 845-855
- https://doi.org/10.2215/cjn.06450710
Abstract
Background and objectives Quality of life (QOL) is markedly impaired in patients with anemia, diabetes mellitus, and chronic kidney disease. Limited data exist regarding the effect of anemia treatment on patient perceptions. The objectives were to determine the longitudinal impact of anemia treatment on quality of life in patients with diabetes and chronic kidney disease and to determine the predictors of baseline and change in QOL. Design, setting, participants, & measurements In a large, double blind study, patients with type 2 diabetes mellitus, nondialysis chronic kidney disease (estimated GFR, 20 to 60 ml/min per 1.73 m2), and anemia (hemoglobin 10.4 g/dl) were randomized to darbepoetin alfa or placebo. QOL was measured with Functional Assessment of Cancer Therapy-Fatigue, Short Form-36, and EuroQol scores over 97 weeks. Results Patients randomized to darbepoetin alfa reported significant improvements compared with placebo patients in Functional Assessment of Cancer Therapy-Fatigue, and EuroQol scores visual analog scores, persisting through 97 weeks. No consistent differences in Short Form-36 were noted. Consistent predictors of worse change scores include lower activity level, older age, pulmonary disease, and duration of diabetes. Interim stroke had a substantial negative impact on fatigue and physical function. Conclusion Darbepoetin alfa confers a consistent, but small, improvement in fatigue and overall quality of life but not in other domains. These modest QOL benefits must be considered in the context of neutral overall effect and increased risk of stroke in a small proportion of patients. Patient's QOL and potential treatment risk should be considered in any treatment decision.Keywords
This publication has 45 references indexed in Scilit:
- Health-Related Quality of Life and Hemoglobin Levels in Chronic Kidney Disease PatientsClinical Journal of the American Society of Nephrology, 2009
- Prospective Study of Long-Term Impact of Adjuvant High-Dose and Conventional-Dose Chemotherapy on Health-Related Quality of LifeJournal of Clinical Oncology, 2007
- Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT)American Heart Journal, 2005
- Combining Anchor and Distribution-Based Methods to Derive Minimal Clinically Important Differences on the Functional Assessment of Cancer Therapy (FACT) Anemia and Fatigue ScalesJournal of Pain and Symptom Management, 2002
- Erythropoietin and anemiaSeminars in Nephrology, 2001
- A Review of Quality-of-Life Evaluations in Patients with Congestive Heart FailurePharmacoEconomics, 1999
- Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaireQuality of Life Research, 1993
- Validating the SF-36 health survey questionnaire: new outcome measure for primary care.BMJ, 1992
- Improvement in exercise capacity after correction of anemia in patients with end-stage renal failureThe American Journal of Cardiology, 1991
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990